Valeant ordered to pay Anacor $100m
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals has won $100m in damages from Valeant Pharmaceuticals for a breach of service agreement related to the development of Anacor's nail fungal drug, tavaborole.